Synonyms: BLU-222 | BLU222
Compound class:
Synthetic organic
Comment: BLU-222 is an oral cyclin-dependent kinase 2 (CDK2)-selective inhibitor from Blueprint Therapeutics. Its chemical structure was revealed during the first time disclosures session at the 2024 ACS spring meeting in New Orleans. BLU-222 is proposed to target solid tumours with CDK2/cyclin E1 amplifications that drive G1/S progression, such as certain ovarian cancers. The chemical structure of BLU-222 is identical to that for the INN cirtociclib (proposed list 132, Feb. 2025).
|
|
References |
1. Brown V, Ramsden P, House N, Vargas R, Guo J, Wang R, Lobbari R, Chen M, Wilson D, Kim J et al..
BLU-222, an investigational, potent, and selective CDK2 inhibitor, demonstrated robust antitumor activity in CCNE1-amplified ovarian cancer models. Accessed on 28/03/2024. Modified on 28/03/2024. blueprintmedicines.com, https://www.blueprintmedicines.com/wp-content/uploads/2022/04/Blueprint-Medicines-AACR-2022-BLU-222-Ovarian-Cancer-Preclinical-Poster.pdf |